Alterations of cerebral blood flow and antiphospholipid antibodies in patients with systemic lupus erythematosus

International Journal of Clinical and Laboratory Research

Volumn 28, Issue 1, 1998, Pages 34-38

  Postiglione, A ^a   De Chiara, S ^a   Soricelli, A ^b   Oriente, A ^a   Ruocco, A ^a   Spadaro, G ^a   Montefusco, S ^a   Marone, G ^a   Genovese, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antiphospholipid antibodies; Cerebral blood flow; Systemic lupus erythematosus

Indexed keywords

CARDIOLIPIN ANTIBODY; DIAGNOSTIC AGENT; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LUPUS ANTICOAGULANT;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD; BRAIN CIRCULATION; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CHILD; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADOLESCENT; ADULT; ANTIBODIES, ANTICARDIOLIPIN; AUTOIMMUNE DISEASES; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; CHILD; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; VASCULITIS;

EID: 0031960501     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005990050015     Document Type: Article

References (38)

1. McCune WJ, Golbus J. Neuropsychiatric lupus. Rheum Dis Clin North Am 1988, 14:159.
2. Bluestein H. Neuropsychiatric manifestations of systemic lupus erythematosus. N Engl J Med 1987; 317:309.
3. Grigor R, Edmonds J, Lewkonia R, Bresnihan B, Hughes GRV. Systemic lupus erythematosus: a prospective analysis. Ann Rheum Dis 1978; 37:121.
4. Dam AP van. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 1991; 11:1.
5. Futrell N, Schultz L, Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. Neurology 1992; 42:1649.
6. Tola MR, Granieri E, Caniatti L, Paolino E, Monetti C, Dovigo L, Scolozzi R, De Bastiani P, Carreras M. Systemic Lupus erythematosus presenting with neurological disorders. J Neurol 1992; 239:61.
7. Love PE, Santoro SA. Antiphospholipids antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non SLE disorders. Ann Intern Med 1990; 112:682.
8. Conley CL, Hartmann RC. A hemorrhagic disorder caused by a circulating anticoagulant in patients with disseminated systemic lupus erythematosus. J Clin Invest 1952; 31:621.
9. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; II: 1211.
10. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117:997.
11. Camerlingo M, Casto L, Censori B, Drago C, Frigeni A, Ferraro B, Servalli MC, Radice E, Mamoli A. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours from onset. Acta Neurol Scand 1995: 92:60.
12. Brey RI, Hart RG, Sherman DG, Tegeler CT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1 190.
13. Ford SE, Kennedy LA, Ford PM. Clinico-pathological correlations of antiphospholipid antibodies. Arch Pathol Lab Med 1994; 118:491.
14. Antiphospholipid Antibodies in Stroke Study (APASS) group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43:2069.
15. Nossent JC, Hovestadt DH, Schonfeld DHW, Swaak AJG. Single-photon emission computed tomography of the brain in the evolution of cerebral lupus. Arthritis Rheum 1991; 34:1397.
16. Maeshima E, Yamada Y, Yukawa S, Nomoto H. Higher cortical dysfunction, antiphospholipid antibodies and neuroradiological examinations in systemic lupus erythematosus. Intern Med 1992; 31:1169.
17. Emmi L, Bramati M, De Cristofaro MT, Mascalchi M, Dal Pozzo G, Marconi GP, Massai G, Passaleva A. MRI and SPECT investigations of the CNS in SLE patients. Clin Exp Rheumatol 1993; 11:13.
18. 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations. Eur J Nucl Med 1995; 22:17.
19. Rogers MP, Waterhouse E, Nagel JS, Roberts NW, Stern SH, Fraser P, Partridge R, Murawski B, Khoshbin S, Holman BL. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus 1992; 1:215.
20. Kodama K, Okada S, Hino T, Takabayashi K, Nawata Y, Uchida Y, Yamanouchi N, Komatus N, Ikeda T, Shinoda N, Murakami A, Sakamoto T, Sato T. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995; 58:307.
21. Tan E, Cohen AS, Fries JF, Masai AT, McShance DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25:1271.
22. Giunta A, Piccillo U, Maione S, Migliaresi S, Valentins G, Arnese M, Losardo L, Marone G, Tirri G, Condorelli M. Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observation and immunological investigation. Acta Cardiol 1993; 48:183.
23. Holman BL, Carvalho PA, Zimmermann RE. Brain perfusion SPECT using an annular single crystal camera: initial clinical experience. J Nucl Med 1990; 31:1456.
24. Holman BL, Johnson KA, Gerada B, Carvalho PA, Scitlin A. The scintigraphic appearance of Alzheimer's disease: aprospective study using technetium-99m HMPAO SPECT. J Nucl Med 1992; 33:523.
25. Snedecor GW, Cochran WG. Statistical methods, 7th edn Iowa: The Iowa State University Press, 1980.
26. Mitchell I, Webb M, Hughes RAC, Maisey M, Cameron S. Cerebral lupus. Lancet 1994; 343:579.
27. Wilson HA, Winfield JB, Lahita RG. Association of IgG-anti brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum 1979; 22:458.
28. Howe A, Dent PB, Liao-SK. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1985; 28:789.
29. Pinching AJ, Travers RL, Hughes GR. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1978; I:898.
30. Antiphospholipid Antibodies in Stroke Study (APASS) group. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 1997; 47:91.
31. Levine SR, Salowich-Palm L, Sawaya RN, Perr M, Spencer HJ, Winkler J, Alam Z, Carey JL. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. Stroke 1997; 28:1660.
32. Gharavi AE. IgG subclasses and light chain distribution of anticardiolipin and antiDNA antibodies in systemic lupus erythematosus. Ann Rheum Dis 1988; 47:286.
33. Sammaritano LR. Significance of aPL IgG subclasses. Lupus 1996; 5:436.
34. Campbell AL, Piperangeli SS, Weilhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73:529.
35. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulant and antibodies to phospholipids. JAMA 1988; 259:550.
36. 2-glycoprotein binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995; 34:1031.
37. Waldemar G. Functional brain imaging with SPECT in normal aging and dementia: methodological, pathophysiological, and diagnostic aspects. Cerebrovasc Brain Metab Rev 1995; 7:89.
38. The Warfarin-Aspirin Recurrent Stroke Study (WARSS), The Antiphospholipid Antibodies and Stroke Study (APASS), The Patent Foramen Ovale in Cryptogenic-Stroke Study (PICASS), The Hemostatic System Activation Study (HAS), The Genes in Stroke (GENESIS) Study. The feasibility of a collaborative double-blind study using anticoagulant. Cerebrovasc Dis 1997; 7:100.